Études d'intervention
02 sep 2014
ODYSSEY FH I et FH II : inhibiteur de PCSK9 dans l’hypercholestérolémie familiale
M. Farnier (France) – Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy : results of ODYSSEY FH I and FH II studies – Hot Line : Coronary artery dis
